COUGH is the #10 most commonly reported adverse reaction for TOBRAMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 428 FDA adverse event reports linking TOBRAMYCIN SULFATE to COUGH. This represents approximately 2.1% of all 20,334 adverse event reports for this drug.
Patients taking TOBRAMYCIN SULFATE who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COUGH428 of 20,334 reports
COUGH is a less commonly reported adverse event for TOBRAMYCIN SULFATE, but still significant enough to appear in the safety profile.
Other Side Effects of TOBRAMYCIN SULFATE
In addition to cough, the following adverse reactions have been reported for TOBRAMYCIN SULFATE:
COUGH has been reported as an adverse event in 428 FDA reports for TOBRAMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COUGH with TOBRAMYCIN SULFATE?
COUGH accounts for approximately 2.1% of all adverse event reports for TOBRAMYCIN SULFATE, making it a notable side effect.
What should I do if I experience COUGH while taking TOBRAMYCIN SULFATE?
If you experience cough while taking TOBRAMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.